J. I. Weitz (1), C. Cao (2), B. I. Eriksson (3), W. Fisher (4), S. Kupfer (2), G. Raskob (5), J. Spaeder (2), A. G. G. Turpie (6)
(1) Thrombosis and Atherosclerosis Research Institute and McMaster University, Hamilton, Ontario, Canada; (2) Takeda Global Research & Development, Inc., Deerfield, Illinois, USA; (3) Sahlgrenska University Hospital / University of Gothenburg, Gothenburg, Sweden; (4) McGill University Health Centre, Montreal, Quebec, Canada; (5) College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA; (6) HHSC McMaster Clinic, McMaster University, Hamilton, Ontario, Canada
This multicentre dose-finding study compared TAK-442, an oral factor Xa inhibitor, with enoxaparin for thromboprophylaxis after knee arthroplasty. In this parallel group study, patients were randomised to oral TAK-442 (40 or 80 mg once-daily [QD] or 10, 20, 40, or 80 mg twice-daily [BID] started 6–8 hours postoperatively), which was blinded as to dose, or to open-label subcutaneous enoxaparin (30 mg BID starting 12–24 hours postoperatively) for 10 days. Treatments were continued until bilateral venography was performed (maximum of 14 days). The primary efficacy endpoint was the composite of any deep-vein thrombosis, non-fatal pulmonary embolism or all-cause mortality, while the primary safety endpoint was major bleeding. Of 1,038 patients randomised who received at least one dose of study drug, 949 completed the study and 730 (76.9%) were evaluable for the primary efficacy analysis. Recruitment into the 10 and 20 mg BID dose groups was stopped early because the incidences of the primary efficacy endpoint were significantly higher than that with enoxaparin. The primary efficacy endpoint occurred in 22.0% of patients given enoxaparin and in 39.0%, 38.4%, 23.5%, 21.4%, 26.8%, and 14.3% of those receiving TAK-442 10 mg BID, 20 mg BID, 40 mg QD, 40 mg BID, 80 mg QD, and 80 mg BID, respectively. The incidences of major and clinically relevant non-major bleeding with TAK-442 were not dose-dependent or different from that with enoxaparin. All TAK-442 doses except 10 and 20 mg BID displayed similar efficacy and safety profiles to enoxaparin.
thromboprophylaxis, venous thromboembolism, anticoagulants, total knee replacement, Oral factor Xa inhibitor
Urs Kistler1, Inès Kramers-de Quervain2, Urs Munzinger3, Nils Kucher4
Thromb Haemost 2008 99 6: 1049-1052
Rupert M. Bauersachs1, Joachim Dudenhausen2, Andree Faridi3, Thorsten Fischer4, Samson Fung5, Ulrich Geisen6, Job Harenberg7, Eberhard Herchenhan8, Franz Keller9, Bettina Kemkes-Matthes10, Helmut Schinzel11, Michael Spannagl12, Christian J. Thaler13, for the EThIG Investigators*
Thromb Haemost 2007 98 6: 1237-1245
William D. Fisher1, Bengt I. Eriksson2, Kenneth A. Bauer3, Lars Borris4, Ola E. Dahl5, Michael Gent6, Sylvia Haas7, Martin Homering8, Menno V. Huisman9, Ajay K. Kakkar10, Peter Kälebo2, Louis M. Kwong11, Frank Misselwitz8, Alexander G. G. Turpie6
Thromb Haemost 2007 97 6: 931-937
Atherosclerosis is an inflammatory and thrombotic disease, in which both CD4+ T cells and...
The May 2013 issue of Thrombosis and Haemostasis 109.5 is a clinically relevant 'state of the art'...
Starting with the April 2013 issue of "Thrombosis and Haemostasis" TH109.4, the ESC...